Palvella Announces FDA Priority Review for Qtorin Rapamycin Application

Riza Dagoc

1 min read

Add as a preferred source on Google

Palvella Announces FDA Priority Review for Qtorin Rapamycin Application

The application seeks U.S. approval for the topical candidate, and Palvella shares traded higher Wednesday.

By Riza Dagoc

Published Oct 28, 2026, 4:48 PM EDT

An unmarked topical medicine tube beside a sealed document sleeve / TokenPost.ai

Palvella Therapeutics, Inc. announced Wednesday that the U.S. Food and Drug Administration granted priority review to its new drug application for Qtorin rapamycin, a topical product candidate seeking U.S. approval.

Qtorin rapamycin is Palvella’s lead product candidate. Shares of Palvella (NASDAQ: PVLA) traded higher Wednesday.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.